Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.76 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.76 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | PRKCB | P05771 | 7/20 | 0.51 |
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | CDK4 | P11802 | 3/20 | 0.51 |
| ▸ | PRKACA | P17612 | 3/20 | 0.51 |
| ▸ | PRKACG | P22612 | 3/20 | 0.51 |
| ▸ | PRKACB | P22694 | 3/20 | 0.51 |
| ▸ | CCND1 | P24385 | 3/20 | 0.51 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | CDK2 | P24941 | 2/20 | 0.51 |
| ▸ | PRKCA | P17252 | 2/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958473 | 0.87 | SIRT2 (1.00) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL3945882 | 0.87 | SIRT2 (1.00) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5686062 | 0.86 | SIRT2 (0.72) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5682704 | 0.82 | SIRT2 (0.65) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5343477 | 0.80 | SIRT2 (0.80) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5682604 | 0.80 | SIRT2 (0.80) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL7504252 | 0.80 | SIRT2 (0.80) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5682562 | 0.80 | SIRT2 (0.61) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL5682637 | 0.78 | SIRT2 (0.76) | SIRT2SIRT1RPS6KB1PRKCBPIM1 | |
| SCHEMBL7195523 | 0.76 | CCNT1 (0.81) | SIRT2SIRT1RPS6KB1PRKCBPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | WYETH | 2006-11-09 | — | — | US | disclosed |
| WO-2005028678-A9 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH CORP (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1636388-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | Wyeth (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005028678-A2 | METHODS AND MATERIALS FOR IDENTIFYING AGENTS WHICH MODULATE BONE REMODELING AND AGENTS IDENTIFIED THEREBY | WYETH (US) | 2005-03-31 | — | — | WO | disclosed |
| US-6719520-B2 | FOR INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3); TREATMENT AND PROPHYLAXIS FOR DIABETES, CHRONIC NEURODEGENERATIVE CONDITIONS, MOOD DISORDERS SUCH AS SCHIZOPHRENIA AND MANIC DEPRESSION AND HAIR LOSS AND CANCER | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20040010031-A1 | Novel method and compounds | SMITHKLINE BEECHAM P.L.C. | 2004-01-15 | — | — | US | disclosed |
| EP-1119548-A1 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021927-A2 | PYRROLE-2,5-DIONES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010031-A1 | Novel method and compounds | GSK3A, GSK3B, GSKIP | SIRT2 468/4885SIRT1 258/4885RPS6KB1 75/4885 |
| US-20060252045-A1 | Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby | BMP4, BMP2, BMP6 | SIRT2 2773/4885SIRT1 2484/4885RPS6KB1 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.